Who’s guilty of “clickbait”? Are spit tubes a bad business? And why are academics emulating Pusha T?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss Novartis’ decision to charge $2.1 million for its gene therapy — and the backlash to news organizations pointing that out. Then, Bloomberg reporter Kristen Brown joins us to discuss how companies are struggling to make money in the world of consumer genetic testing. Finally, we delve into a scandal at MIT that finds one professor accusing another of academic malfeasance.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy